Search results
Earnings call: Aclaris Therapeutics progresses with atopic dermatitis study By Investing.com
Investing.com· 5 days agoAclaris Therapeutics, Inc. (NASDAQ:ACRS) has announced during its First Quarter 2024 Conference Call...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue
WKRN Nashville· 3 days agoNEW YORK, May 10, 2024 Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against bluebird bio, Inc. ("Blue" or the "Company") (NASDAQ: BLUE) and ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird...
WTRF Wheeling· 7 days agoThe Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to ...
Wellbutrin vs Adderall: Important Differences You Should Know
MediaFeed via AOL· 5 days agoAnxiety and depression are two common mental conditions — it’s estimated that about 40 million...
May 10 2024 This Week in Cardiology
Medscape· 4 days agoFor more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast, download the Medscape app or subscribe on Apple...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit...
Benzinga· 3 days agoYou can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. On December 8, 2023, bluebird ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoRobbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock ...